Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04385953 · ClinicalTrials.gov registry record

QStat in Trauma and Obstetric Hemorrhage

A clinical trial of Trauma and Postpartum Hemorrhage, sponsored by HemoSonics.

Completed
Registry status
22
Enrollment target
1
Study location

NCT04385953: Completed study of Trauma and Postpartum Hemorrhage, sponsored by HemoSonics.

NCT04385953 is a study of Trauma and Postpartum Hemorrhage that has completed, run by HemoSonics. The registered enrollment target is 22 participants, below the 307-participant average among 56 other Trauma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04385953, a study of Trauma and Postpartum Hemorrhage, has completed, sponsored by HemoSonics.

COMPLETED
Registry status
22 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QStat Cartridge in trauma patients and obstetric patients with postpartum hemorrhage.

Primary Outcome

Coagulation function assessed by Quantra and ROTEM delta

Interventions

  • DIAGNOSTIC_TEST Quantra System

Study Locations (1)

California

  • Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-12-10
Est. Completion 2020-08-01
HemoSonics

24 total trials

What the finished NCT04385953 record still lists

NCT04385953 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 307-participant average among 56 other Trauma trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Trauma appearing as the primary indexed condition, and to 1 intervention - of which Quantra System is the first listed.

NCT04385953 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04385953 about?

NCT04385953 is a clinical study titled "QStat in Trauma and Obstetric Hemorrhage". This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QStat Cartridge in trauma patients and obstetric patients with postpartum hemorrhage.

What is the current status of trial NCT04385953?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2019-12-10. Estimated completion is 2020-08-01.

What conditions does trial NCT04385953 study?

This clinical trial studies the following conditions: Trauma, Postpartum Hemorrhage, Blood Loss Massive.

What interventions are being tested in trial NCT04385953?

The interventions under investigation include: Quantra System (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04385953?

This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04385953 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trauma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04385953's enrollment target sits among peer trials

22 50th of 56 higher than 7 of 56 other Trauma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Trauma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04385953, the US trial registry maintained by the National Library of Medicine. NCT04385953 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.